Ascendis Pharma A/S
ASND
Rang în acțiuni
#1502
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing... Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Preț acțiune
$234.33
Capitalizare de piață
$14.62B
Schimbare (1 zi)
1.90%
Schimbare (1 an)
14.19%
Țară
DK
Tranzacționează Ascendis Pharma A/S (ASND)
Categorie
Healthcare
Raport P/B pentru Ascendis Pharma A/S (ASND)
Raport P/B la data de October 2026 TTM: 9.08
Conform celor mai recente rapoarte financiare și prețului acțiunilor Ascendis Pharma A/S, raportul P/B actual (TTM) este 9.08. La sfârșitul anului 2023, compania avea un P/B de -44.02.
Istoricul raportului P/B pentru Ascendis Pharma A/S din 2011 până în 2026
Raport P/B la sfârșitul fiecărui an
| An | Raport P/B | Schimbă |
|---|---|---|
| 2026 (TTM) | 9.08 | -112.46% |
| 2024 | -72.81 | 65.40% |
| 2023 | -44.02 | -281.27% |
| 2022 | 24.28 | 231.17% |
| 2021 | 7.33 | -10.96% |
| 2020 | 8.24 | -14.77% |
| 2019 | 9.66 | 20.55% |
| 2018 | 8.01 | 34.59% |
| 2017 | 5.95 | 105.99% |
| 2016 | 2.89 | -12.94% |
| 2015 | 3.32 | -42.28% |
| 2014 | 5.75 | -75.49% |
| 2013 | 23.47 | -76.31% |
| 2012 | 99.06 | 0.00% |
| 2011 | 0.00 | 0.00% |
Raport P/B pentru companii similare sau competitoare
| Companie | Raport P/B | Diferență raport P/B | Țara |
|---|---|---|---|
| 6.251 | -31.12% |
US
|
|
| 13.2547 | 46.05% |
US
|
|
| 4.208 | -53.63% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -31.88% |
NL
|
